Company Overview and News


Add VNDA
to your dashboard

Headline News

BRIEF-Vanda receives negative opinion for marketing authorization from the European Medicines Agency

2017-11-10 reuters
* Vanda receives negative opinion for marketing authorization from the European Medicines Agency on fanaptum™ for the treatment of schizophrenia (1-0)

Vanda Pharmaceuticals' (VNDA) CEO Mihael Polymeropoulos on Q3 2017 Results - Earnings Call Transcript

2017-11-08 seekingalpha
Welcome to the Q3 2017 Vanda Pharmaceuticals Inc. Earnings Conference Call. My name is Leslie and I will be your operator for today. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session. [Operator Instructions] Please note that this conference is being recorded. (1-0)

Bioscience Catalysts: Global Blood Therapeutics And Vanda Pharmaceuticals

2017-10-31 seekingalpha
The bioscience catalyst series seeks to help readers making sense of the notable life science runners. (61-1)

Vanda Pharmaceuticals Announces Participation at the Oppenheimer Specialty Pharma Summit Conference

2017-10-10 prnewswire
WASHINGTON, Oct. 10, 2017 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today announced that it will host investor meetings at the Oppenheimer Specialty Pharma Summit Conference in New York City on Wednesday, October 11, 2017. (1-0)

Great Point Partners Llc - Current Holdings - Fintel.io

2017-10-10 fintel.io
Great Point Partners Llc has disclosed 38 total holdings in their latest SEC filings. Most recent portfolio value is calculated to be $ 486,757,000 USD. Actual Assets Under Management (AUM) is this value plus cash (which is not disclosed). Great Point Partners Llc's top holdings are Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) , Vanda Pharmaceuticals, Inc. (NASDAQ:VNDA) , Zogenix, Inc. (NASDAQ:ZGNX) , PTC Therapeutics, Inc. (362-10)

Vanda to Present Tradipitant Phase II Atopic Dermatitis Data at World Congress of Itch

2017-10-02 prnewswire
WASHINGTON, Oct. 2, 2017 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (VANDA) (NASDAQ: VNDA) today announced that data from the results of the Phase II study of tradipitant in atopic dermatitis will be presented at the 9th World Congress of Itch in Wroclaw Poland as a late breaking entry in the scientific poster forum on October 16 and 17.  On September 13, 2017, Vanda announced that tradipitant improved both itch and disease severity in patients with atopic dermatitis. (1-0)

Technical Reports on Biotech Equities -- Vanda Pharma, ACADIA Pharma, Achillion Pharma, and Agios Pharma

2017-09-20 prnewswire
If you want a Stock Review on VNDA, ACAD, ACHN, or AGIO then come over to http://dailystocktracker.com/register/ and sign up for your free customized report. For today, DailyStockTracker.com monitors Vanda Pharmaceuticals Inc. (NASDAQ: VNDA), ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), Achillion Pharmaceuticals Inc. (NASDAQ: ACHN), and Agios Pharmaceuticals Inc. (NASDAQ: AGIO). These stocks belong to the Biotechnology space, which consists of companies engaged in the research and development of new drugs, medical devices, and procedures. (175-0)

Vanda Drops on Mixed Dermatitis Drug Trial Data

2017-09-14 biospace
WASHINGTON, Sept. 13, 2017 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today announced results from an 8-week randomized Phase II clinical study of tradipitant as a monotherapy in the treatment of chronic pruritus in patients with atopic dermatitis. Tradipitant was shown to improve the intensity of the worst itch patients experienced, as well as atopic dermatitis disease severity.

BRIEF-Vanda Pharmaceutical ‍announced results from study of Tradipitant as a treatment of chronic pruritus

2017-09-13 reuters
* Vanda Pharmaceuticals Inc - ‍announced results from randomized phase ii clinical study of Tradipitant as a monotherapy in treatment of chronic pruritus

Vanda's Tradipitant Improves Itch and Disease Severity in Patients with Atopic Dermatitis

2017-09-13 prnewswire
-- Worst Itch Visual Analog Scale (Worst Itch VAS): Tradipitant vs. Placebo p=0.019 -- Scoring Atopic Dermatitis (SCORAD): Tradipitant vs. Placebo p=0.008 Management to host conference call on Thursday, September 14 at 8:30 AM ET

Strength Seen in Vascular Biogenics (VBLT): Stock Jumps 5.3%

2017-08-16 zacks
Vascular Biogenics Ltd. (VBLT - Free Report) was a big mover last session, as the company saw its shares rise over 5% on the day. The move came on solid volume with far more shares changing hands than in a normal session. This breaks the recent trend of the company, as the stock is now trading above the volatile price range of $4.05 to $4.65 in the past one-month time frame.

Vanda Pharmaceuticals' (VNDA) CEO Mihael Polymeropoulos on Q2 2017 Results - Earnings Call Transcript

2017-08-03 seekingalpha
Welcome to the Q2 2017 Vanda Pharmaceuticals Earnings Conference Call. My name is Victoria and I will be your operator for today's call. At this time, all participants are in a listen only mode. And later, we will conduct a question-and-answer session. [Operator Instructions] Please note that this conference is being recorded.

CUSIP: 921659108